Background. the genetic diversity of human immunodeficiency virus type 1 (HIV-1) raises the question of whether vaccines that include a component to elicit antiviral T cell immunity based on a single viral genetic clade could provide cellular immune protection against divergent HIV-1 clades. Therefore, we quantified the cross-clade reactivity, among unvaccinated individuals, of anti-HIV-1 T cell responses to the infecting HIV-1 clade relative to other major circulating clades.Methods. Cellular immune responses to HIV-1 clades A, B, and C were compared by standardized interferon-gamma enzyme-linked immunospot assays among 250 unvaccinated individuals, infected with diverse HIV-1 clades, from Brazil, Malawi, South Africa, Thailand, and the Un...
Background: HIV-1-infected individuals who spontaneously control viral replication represent an exam...
The genetic diversity among globally circulating human immunodeficiency virus type 1 (HIV-1) strains...
The high level of genetic diversity of HIV-1 poses a major challenge for global vaccine development....
An effective HIV type 1 (HIV-1) vaccine will likely require elicitation of broadly reactive cell-med...
An effective HIV type 1 (HIV-1) vaccine will likely require elicitation of broadly reactive cell-med...
The genetic diversity of HIV-1 across the globe is a major challenge for developing an HIV vaccine. ...
A globally effective vaccine will need to elicit cytotoxic T lymphocytes (CTL) capable of recogniz-i...
We have examined cross-clade HIV-specific cytotoxic T-lymphocyte (CTL) activity in peripheral blood ...
We have examined cross-clade HIV-specific cytotoxic T-lymphocyte (CTL) activity in peripheral blood ...
Background: HIV-1-infected individuals who spontaneously control viral replication represent an exam...
The genetic diversity of HIV-1 across the globe is a major challenge for developing an HIV vaccine. ...
A systematic analysis of immune responses on a population level is critical for a human immunodefici...
An effective HIV-1 vaccine should elicit sufficient breadth of immune recognition to protect against...
The genetic diversity of HIV-1 across the globe is a major challenge for developing an HIV vaccine. ...
AbstractWe studied cytotoxic T lymphocyte (CTL) cross-reactivity between human immunodeficiency viru...
Background: HIV-1-infected individuals who spontaneously control viral replication represent an exam...
The genetic diversity among globally circulating human immunodeficiency virus type 1 (HIV-1) strains...
The high level of genetic diversity of HIV-1 poses a major challenge for global vaccine development....
An effective HIV type 1 (HIV-1) vaccine will likely require elicitation of broadly reactive cell-med...
An effective HIV type 1 (HIV-1) vaccine will likely require elicitation of broadly reactive cell-med...
The genetic diversity of HIV-1 across the globe is a major challenge for developing an HIV vaccine. ...
A globally effective vaccine will need to elicit cytotoxic T lymphocytes (CTL) capable of recogniz-i...
We have examined cross-clade HIV-specific cytotoxic T-lymphocyte (CTL) activity in peripheral blood ...
We have examined cross-clade HIV-specific cytotoxic T-lymphocyte (CTL) activity in peripheral blood ...
Background: HIV-1-infected individuals who spontaneously control viral replication represent an exam...
The genetic diversity of HIV-1 across the globe is a major challenge for developing an HIV vaccine. ...
A systematic analysis of immune responses on a population level is critical for a human immunodefici...
An effective HIV-1 vaccine should elicit sufficient breadth of immune recognition to protect against...
The genetic diversity of HIV-1 across the globe is a major challenge for developing an HIV vaccine. ...
AbstractWe studied cytotoxic T lymphocyte (CTL) cross-reactivity between human immunodeficiency viru...
Background: HIV-1-infected individuals who spontaneously control viral replication represent an exam...
The genetic diversity among globally circulating human immunodeficiency virus type 1 (HIV-1) strains...
The high level of genetic diversity of HIV-1 poses a major challenge for global vaccine development....